There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
2 responses
2,505 views
0 reactions
|
by skbrimer
02-02-2016, 07:07 AM
|
|||
|
5 responses
9,701 views
0 reactions
|
by Bertha77
01-30-2016, 08:13 AM
|
|||
|
4 responses
3,042 views
0 reactions
|
by kerplunk412
01-27-2016, 03:29 PM
|
|||
|
1 response
1,554 views
0 reactions
|
01-27-2016, 06:29 AM
|
|||
|
3 responses
4,422 views
0 reactions
|
by kerplunk412
01-25-2016, 03:41 PM
|
|||
|
2 responses
3,657 views
0 reactions
|
by seqsyd
01-22-2016, 03:41 AM
|
|||
|
3 responses
1,754 views
0 reactions
|
01-21-2016, 03:43 PM
|
|||
|
46 responses
27,848 views
0 reactions
|
by saida
01-21-2016, 11:00 AM
|
|||
|
1 response
3,308 views
0 reactions
|
01-20-2016, 05:40 PM
|
|||
|
1 response
2,098 views
0 reactions
|
by qsonica
01-18-2016, 11:18 AM
|
No topics found.
-
Next-generation sequencing (NGS) is now central to outbreak investigations and antimicrobial resistance tracking. Through sophisticated...07-31-2026, 07:00 AM
-
The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.
This convergence of genetics, immunology, and computation...09-01-2026, 05:41 AM -
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM